Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.61 -2.26%

-$0.42 today

Market cap
$1.96B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 0.88M

Average 1.23M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$190.92M

FY 2025 · Annual

Investing Cash Flow

$60.80M

FY 2025 · Annual

Financing Cash Flow

$640.36M

FY 2025 · Annual

+166.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Depreciation & Amortization755K631K728K2.1M2.96M
Deferred Income Tax(500K)(7.27M)000
Stock-Based Compensation3.45M5.33M6.22M15.75M25.69M
Change in Working Capital2.78M2.24M12M14.87M(15.23M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.78M(677K)(608K)9.53M(9.16M)
Other Working Capital998K2.92M12.61M5.35M(6.06M)
Other Non-Cash Items4K7.27M80.29M149.45M8.06M
Operating Cash Flow(18.23M)(28.69M)(7.57M)(110.79M)(190.92M)
Capital Expenditures(79K)(248K)(831K)(53.51M)(9.69M)
Acquisitions (Net)009.28M00
Purchases of Investments00(38.93M)(186.56M)(123.27M)
Sales of Investments000155M200M
Other Investing Activities000(46.34M)(6.25M)
Investing Cash Flow(79K)(248K)(30.48M)(85.06M)60.8M
Debt Repayment(113K)0000
Common Stock Issued27.23M32K34K250M640.36M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities656K0116.37M(9.47M)0
Financing Cash Flow27.77M32K116.41M240.53M640.36M
Effect of Forex Changes00000
Net Change in Cash9.46M(28.91M)78.36M44.67M510.24M
Free Cash Flow(18.31M)(28.94M)(8.4M)(164.3M)(200.6M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$212.4M
+ D&A$3.0M
+ Stock-Based Comp$25.7M
+ Deferred Tax$0
- Working Capital-$15.2M
+ Other Non-Cash$8.1M
= Operating Cash Flow-$190.9M
- Capex-$9.7M
= Free Cash Flow-$200.6M

Analysis

FY2025 free cash flow is -$200.6M. FCF conversion is 94.4% of net income. Operating cash flow was -$190.9M, with capex of -$9.7M. The largest bridge item is Stock-Based Comp at $25.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3ASRS-3ASR filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
S-3ASRS-3ASR filingNov 9, 2026
SC 13GSC 13G filingOct 30, 2026

Does IMNM generate free cash flow?

Immunome, Inc. (IMNM) generated -$200.60M of free cash flow in fiscal 2025.

How much operating cash flow does IMNM produce?

Operating cash flow was -$190.92M, before capital expenditures of $9.69M.